{"DataElement":{"publicId":"3235993","version":"1","preferredName":"in vivo Monoclonal Antibody Administered Type","preferredDefinition":"A description of in vivo monoclonal antibody administered.","longName":"2787457v1.0:3235988v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2787457","version":"1","preferredName":"in vivo Monoclonal Antibody Administered","preferredDefinition":"Located or occurring in the body._An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.__The act of having given something (e.g., a medication or test).","longName":"INVIV_MON_ADMIN","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2861828","version":"1","preferredName":"in vivo Monoclonal Antibody","preferredDefinition":"Located or occurring in the body; the opposite of in vitro (located or occurring outside the body).:An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.","longName":"C15744:C20401","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Vivo","conceptCode":"C15744","definition":"Located or occurring in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6813B832-42DC-0C93-E040-BB89AD435C71","latestVersionIndicator":"Yes","beginDate":"2009-04-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-04-21","modifiedBy":"ONEDATA","dateModified":"2009-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"57AA4D58-8C49-55AA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-24","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3235988","version":"1","preferredName":"in vivo Monoclonal Antibody Type","preferredDefinition":"Located or occurring in the body._An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment._Type; a subdivision of a particular kind of thing.","longName":"3235988v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3A5B528-81D4-24F1-E040-BB89AD433F46","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"ONEDATA","dateModified":"2011-05-19","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":"Rituximab","ValueMeaning":{"publicId":"2738482","version":"1","preferredName":"Rituximab","longName":"2738482","preferredDefinition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F890-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3A5B528-81DE-24F1-E040-BB89AD433F46","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"ONEDATA","dateModified":"2011-05-19","deletedIndicator":"No"},{"value":"Muromonab","valueDescription":"Muromonab-CD3","ValueMeaning":{"publicId":"3235989","version":"1","preferredName":"Muromonab-CD3","longName":"3235989","preferredDefinition":"A murine IgG2a monoclonal antibody with potential immunosuppressive activity. Muromonab-CD3 specifically targets and binds to the T-cell receptor CD3 complex on the surface of circulating T-lymphocytes, which mediates antigen recognition process. Binding of muromonab-CD3 to CD3-positive T cells may result initially in an early activation of this T cell subset, followed by cytokine release. Long-term administration of this agent eventually may cause the opsonization and elimination of CD3-positive T cells, thereby resulting in a loss of functional effector T cells and a suppression of the immune system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Muromonab-CD3","conceptCode":"C1321","definition":"A murine IgG2a monoclonal antibody with immunosuppressive activity. Muromonab-CD3 binds to and inhibits CD3 on the surface of circulating T-lymphocytes; binding of muromonab-CD3 to CD3-positive T cells results in an early activation of this T cell subset, followed by cytokine release, and subsequently inhibition of T cell functions. This agent may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3A5B528-81EA-24F1-E040-BB89AD433F46","latestVersionIndicator":"Yes","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3A5B528-8203-24F1-E040-BB89AD433F46","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"ONEDATA","dateModified":"2011-05-19","deletedIndicator":"No"},{"value":"Infliximab","valueDescription":"Infliximab","ValueMeaning":{"publicId":"3235990","version":"1","preferredName":"Infliximab","longName":"3235990","preferredDefinition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis.  Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infliximab","conceptCode":"C1789","definition":"A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3A5B528-820D-24F1-E040-BB89AD433F46","latestVersionIndicator":"Yes","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3A5B528-8225-24F1-E040-BB89AD433F46","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"ONEDATA","dateModified":"2011-05-19","deletedIndicator":"No"},{"value":"Etanercept","valueDescription":"Etanercept","ValueMeaning":{"publicId":"3235991","version":"1","preferredName":"Etanercept","longName":"3235991","preferredDefinition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etanercept","conceptCode":"C2381","definition":"A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3A5B528-822F-24F1-E040-BB89AD433F46","latestVersionIndicator":"Yes","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"MAESKEB","dateModified":"2022-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3A5B528-8248-24F1-E040-BB89AD433F46","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"ONEDATA","dateModified":"2011-05-19","deletedIndicator":"No"},{"value":"Daclizumab","valueDescription":"Daclizumab","ValueMeaning":{"publicId":"2576091","version":"1","preferredName":"Daclizumab","longName":"2576091","preferredDefinition":"A monoclonal antibody that is being studied for treatment of adult T-cell leukemia.  Also called dacliximab.  Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daclizumab","conceptCode":"C1569","definition":"A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F648-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3A5B528-8254-24F1-E040-BB89AD433F46","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"ONEDATA","dateModified":"2011-05-19","deletedIndicator":"No"},{"value":"Alemtuzumab","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A3A5B528-8268-24F1-E040-BB89AD433F46","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"ONEDATA","dateModified":"2011-05-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3235987","version":"1","preferredName":"in vivo Monoclonal Antibody Type","preferredDefinition":"Located or occurring in the body; the opposite of in vitro (located or occurring outside the body).:An antibody produced by a clone or genetically homogenous population of hybrid cells i.e., hybridoma; hybrid cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis and treatment.:Type; a subdivision of a particular kind of thing.","longName":"C15744:C20401:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Vivo","conceptCode":"C15744","definition":"Located or occurring in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3A5B528-81AD-24F1-E040-BB89AD433F46","latestVersionIndicator":"Yes","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"ONEDATA","dateModified":"2011-05-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3A5B528-81BE-24F1-E040-BB89AD433F46","latestVersionIndicator":"Yes","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"KUMMEROA","dateModified":"2014-01-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"3638517","version":"1","longName":"2031r2: Immune Deficiencies Pre-HSCT Data","context":"NHLBI"},{"publicId":"3234637","version":"1","longName":"2131r2: Immune Deficiencies Post-HSCT Data","context":"NHLBI"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the type of the in vi","type":"Preferred Question Text","description":"What is the type of the in vivo monoclonal antibody administered?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3A5B528-8279-24F1-E040-BB89AD433F46","latestVersionIndicator":"Yes","beginDate":"2011-05-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-05-19","modifiedBy":"KUMMEROA","dateModified":"2014-10-16","changeDescription":". Added human readable def. System generated def displayed as alt def. No version needed. AK 10/16/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}